- cafead   Apr 05, 2022 at 11:52: PM
via Under pressure to diversify from the blockbuster cancer med Keytruda, Merck & Co. is looking to its cardiovascular portfolio in hopes of finding $10 billion in peak revenue by the mid-2030s—depending on the approval of eight potential therapies.
article source
article source